EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities

Rachel S Goodman, Seungyeon Jung, Justin M Balko, Douglas B Johnson iD

Immunological Reviews · 2023-09 · 318 (1) · 157-166

DOI: 10.1111/imr.13249 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 20.07.2023. Verfasst von Rachel S Goodman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Colorectal Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Burroughs Wellcome Fund, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still constrained by lack of response and toxicity. Biomarkers of response may facilitate drug development by allowing appropriate therapy selection and focusing clinical trial enrollment. However, aside from PD‐L1 staining in a subset of tumors and rarely mismatch repair deficiency, no biomarkers are routinely used in the clinic. In addition, severe toxicities may cause severe morbidity, therapy discontinuation, and even death. Here, we review the state of the field with a focus on our research in therapeutic biomarkers and toxicities from immune checkpoint inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsColorectal NeoplasmsNeoplastic Syndromes, HereditaryHumansImmune Checkpoint InhibitorsBiomarkersImmunotherapyBiomarkers, Tumor

Stichwörter der Autor:innen

MHC-IIbiomarkersimmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapytumor mutational burden

Substanzen

Immune Checkpoint InhibitorsBiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Department of Medicine, Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Douglas B Johnson

Förderung

  • NCI NIH HHS
  • Burroughs Wellcome Fund
  • National Cancer Institute

Zitieren

APA

Goodman, R. S., Jung, S., Balko, J. M., & Johnson, D. B. (2023). Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. Immunological Reviews, 318(1), 157-166. https://doi.org/10.1111/imr.13249

Vancouver

Goodman RS, Jung S, Balko JM, Johnson DB. Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. Immunological Reviews. 2023;318(1):157-166. doi:10.1111/imr.13249

BibTeX
@article{Goodman2023,
  author = {Goodman, Rachel S and Jung, Seungyeon and Balko, Justin M and Johnson, Douglas B},
  title = {Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities},
  journal = {Immunological Reviews},
  year = {2023},
  volume = {318},
  number = {1},
  pages = {157--166},
  doi = {10.1111/imr.13249}
}
Kostenlos starten →